Render Target: STATIC
Render Timestamp: 2025-01-03T11:41:24.210Z
Commit: 286c369131ceeedcf44c821941824d8d7e009e57
XML generation date: 2024-11-18 16:03:15.003
Product last modified at: 2025-01-01T09:02:10.003Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

β-Synuclein (F8O8P) Rabbit mAb #82400

Filter:
  • IF

    Supporting Data

    REACTIVITY M
    SENSITIVITY Endogenous
    MW (kDa) 18
    Source/Isotype Rabbit IgG
    Application Key:
    • IF-Immunofluorescence 
    Species Cross-Reactivity Key:
    • M-Mouse 

    Product Information

    Product Usage Information

    Application Dilution
    Immunofluorescence (Frozen) 1:800 - 1:1600

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    β-Synuclein (F8O8P) Rabbit mAb recognizes endogenous levels of total β-synuclein protein. This antibody does not cross-react with α-synuclein. 

    Species Reactivity:

    Mouse

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro90 of human β-synuclein protein.

    Background

    The synuclein family, consisting of α-synuclein, β-synuclein, and γ-synuclein, is a group of small, soluble proteins containing a highly conserved α-helical lipid-binding motif. α-synuclein and β-synuclein are primarily expressed in brain tissue, where they colocalize within presynaptic terminals (1,2). α-synuclein is linked genetically and neuropathologically to Parkinson’s disease and other neurodegenerative diseases, called synucleinopathies, characterized by the presence of intracellular α-synuclein aggregates, the main component of Lewy bodies (3,4). β-synuclein has been shown to inhibit α-synuclein aggregation and ameliorate α-synuclein neurotoxicity (5-7). Studies have shown that β-synuclein levels are elevated in early and advanced Alzheimer’s disease, Creutzfeldt-Jakob disease, and traumatic brain injury, showing strong potential for use as a synaptic damage biomarker (8-9).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.